Strongbridge Biopharma plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Strongbridge Biopharma plc
Pieris and Genentech try partnering again after a disappointing IO tie-up before. Biogen’s hectic May includes partnerships with Ginkgo, Envisagenics, Capsigen and an opt-in on TMS’s stroke candidate.
Having been given a PDUFA target date of 1 January, 2022, Strongbridge is already preparing for a happy new year challenging Recordati's Isturisa for market share in the Cushing's syndrome space
News and highlights of applications submitted for US FDA approval, from the Pink Sheet’s FDA Performance Tracker
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
- Other Names / Subsidiaries
- BioPancreate Inc., Cortendo AB
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.